Is Bergamot Cholesterol Randomized Trial safe?

Updated July 2026

Quick Answer

Bergamot Cholesterol Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Data extraction focused on weight loss, body mass index, waist circumference, waist-to-hip ratio, and body fat percentage, and the risk of bias was assessed using the Revised Cochrane Risk-of-Bias Tool.

Key Takeaways

  • 01Data extraction focused on weight loss, body mass index, waist circumference, waist-to-hip ratio, and body fat percentage, and the risk of bias was assessed using the Revised Cochrane Risk-of-Bias Tool. [Pujia C (2026)]
  • 02This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess the effect of nutraceuticals containing Citrus bergamia on the management of obesity in adults by assessing measures related to obesity. [Pujia C (2026)]
  • 03We searched the following databases until October 2024: PubMed, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials. [Pujia C (2026)]
  • 041 2 3 2 3 4 5 6 Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, primarily driven by a combination of non-modifiable (gender and family history) and modifiable (e.g., dyslipidemia, hypertension, smoking, diabetes, and obesity) risk factors. [Carpenito Myriam (2025)]
The current Migaku evidence database contains 2 reusable source documents for Bergamot Cholesterol Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Data extraction focused on weight loss, body mass index, waist circumference, waist-to-hip ratio, and body fat percentage, and the risk of bias was assessed using the Revised Cochrane Risk-of-Bias Tool. [Pujia C (2026); evidence level 1] - This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess the effect of nutraceuticals containing Citrus bergamia on the management of obesity in adults by assessing measures related to obesity. [Pujia C (2026); evidence level 1] - We searched the following databases until October 2024: PubMed, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials. [Pujia C (2026); evidence level 1] - 1 2 3 2 3 4 5 6 Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, primarily driven by a combination of non-modifiable (gender and family history) and modifiable (e.g., dyslipidemia, hypertension, smoking, diabetes, and obesity) risk factors. [Carpenito Myriam (2025); evidence level 3] - Among modifiable risk factors, low-density lipoprotein cholesterol (LDL-C) is recognized as the most significant contributor to atherosclerosis [,,]. [Carpenito Myriam (2025); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Effect of Citrus bergamia Supplementation on Body Composition in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
  2. Unveiling the Power of Bergamot: Beyond Lipid-Lowering Effects